Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

need for women and for physicians seeking alternatives to hormone therapies."

Dr. Alan Altman, Assistant Clinical Professor of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School and an expert on menopause, commented "Physicians are now seeing an epidemic of vaginal symptoms, such as dryness, irritation and sexual pain, in post-menopausal patients as a result of large numbers of women stopping hormone treatment due to fear instilled by what they have read about the Women's Health Initiative Study. Chronic symptoms such as these have a major adverse impact on quality of life for these women and highlight the need for new treatment options in those wanting to avoid estrogen use."

About Postmenopausal Vaginal Syndrome

Postmenopausal Vaginal Syndrome (PVS) is a chronic condition characterized by vaginal symptoms including dryness, sexual pain (dyspareunia), and irritation. Declining estrogen levels during menopause may cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with decreases in vaginal secretions often cause pain or bleeding during sexual intercourse. The decline in estrogen also contributes to an increase in vaginal pH, creating an environment more susceptible to infection. There are more than 64 million women in the United States who are over 40 years old. It is estimated that up to 40% of post-menopausal women will have symptoms of PVS. Current treatments approved for this condition all contain estrogen, administered either orally or locally in the vagina. Other currently available SERMs do not have an effect on vaginal tissue and may induce hot flashes.

About QuatRx

QuatRx Pharmaceuticals is focused on the discovery, licensing, development and commercialization of compounds in the endocrine, metabolic and cardiovascular therapeutic areas. In addition to Ophena(TM), QuatRx has three other product candidates in active cl
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  Publicis Groupe customer engagement agency Rosetta ... Healthcare Industry Group Leader, has been featured in the ... inspiring people in the life-sciences industry. Those chosen for ... marketing, technology, creativity, strategy and medicine. ... in its leading Rosetta Consulting practice. In 2012, she ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... Inc. for the third straight year, No. 349 ... an exclusive ranking of the nation,s fastest-growing private ... at the most important segment of the economy—America,s ... Dell, Domino,s Pizza, LinkedIn, Zillow, and many other ...
(Date:8/21/2014)... Aug. 21, 2014  Zacks.com announces the list of stocks ... Research analysts discuss the latest news and events impacting stocks ... include the Hewlett-Packard (NYSE: HPQ - Free Report ), IBM ... (NYSE: SB - Free Report ), GlaxoSmithKline plc (NYSE: ... (NYSE: FI - Free Report ). Today, ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical and medical applications, announced its recent ... Advances in Skin and Wound Care held in ...
... GAITHERSBURG, Md., Nov. 1, 2011 /PRNewswire-iReach/ ... specialty pharmaceutical company focused exclusively in the HIV-1 ... DFH an exclusive research license with an option ... maturation inhibitor program.  Maturation inhibitors are a novel ...
Cached Medicine Technology:Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 2Misonix Exhibits at 26th Annual Clinical Symposium on Advances in Skin and Wound Care 3DFH Pharma Obtains Exclusive Rights to Second-Generation HIV Maturation Inhibitor Program 2DFH Pharma Obtains Exclusive Rights to Second-Generation HIV Maturation Inhibitor Program 3DFH Pharma Obtains Exclusive Rights to Second-Generation HIV Maturation Inhibitor Program 4
(Date:8/22/2014)... provides insight on how the brain processes external input ... and sides of the body, in order to select ... in the journal Neuron , show that the ... of sensory information, with specialised functional roles for the ... input structure in the basal ganglia, and is typically ...
(Date:8/22/2014)... the dramatic images of nurses at New York University,s ... patients, carrying many including the youngest and most vulnerable ... from the storm surge generated by Hurricane Sandy. ... New York University Colleges of Nursing (NYUCN) and of ... Health examines the impact on NYULMC nurses, post-Sandy ...
(Date:8/22/2014)... 22, 2014 The ALS Association, along ... Center at Allegheny Health Network as a ... at Allegheny General Hospital (AGH), is the only ALS ... Association for meeting the highest levels of established national ... sclerosis (ALS), often referred to as Lou Gehrig’s Disease. ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The New ... at Rutgers, the State University of New Jersey ... innovative children’s media organization, to educate young people about ... build on the strengths of both organizations. , The ... a health communications fellowship program, and video communications. ...
(Date:8/22/2014)... HealthDay Reporter THURSDAY, Aug. ... workers infected with the deadly Ebola virus while doing ... from the Atlanta hospital where they have been slowly ... Kent Brantly, 33, was released from Emory University Hospital ... Her family said the 59-year-old woman is still weak ...
Breaking Medicine News(10 mins):Health News:The striatum acts as hub for multisensory integration 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 2Health News:Allegheny Health Network ALS Program Named Certified Treatment Center of Excellence 3Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Both U.S. Health-Care Workers Infected With Ebola Released From Hospital 2Health News:Both U.S. Health-Care Workers Infected With Ebola Released From Hospital 3
... $0.18 Earnings per Share, BILLERICA, Mass., Oct. 23 ... provider of precision technology and,semiconductor systems, today announced financial ... Third quarter revenue was $84.0 million, compared to $73.1 ... for the third quarter of 2006.,Excluding restructuring charges, operating ...
... Aflac Incorporated,today reported its third quarter results. Reflecting ... 5.1% to $3.9,billion during the third quarter of 2007, ... Net earnings were $420 million, or $.85 per diluted,share, ... year ago. Net,earnings included realized investment gains of $1 ...
... With the discovery of suitable molecular targets cellular ... cancer cells comes the perplexing dilemma of where ... and disable those targets. While the possibilities for drug ... and repositories are often problematic or ill-suited for the ...
... clay in unvented kilns could be a significant source ... periods, a new study suggests. , The results came ... the University of Michigan Dioxin Exposure Study, which measured ... River flood plain between Midland and Saginaw. , The ...
... SAN FRANCISCO -- Mayo Clinic today reported promising interim ... combination therapy for patients with recurrent ovarian cancer that ... participants achieved either complete or partial tumor regression from ... Findings from this Phase 2 Consortium (P2C) clinical trial ...
... Disorder Without Disturbing Patients, CHICAGO, Oct. 23 ... measuring airflow by nasal pressure, temperature, and/or carbon,dioxide, ... method is,uncomfortable to some and can potentially disturb ... 73rd annual international scientific assembly,of the American College ...
Cached Medicine News:Health News:GSI Group Reports Third Quarter Results 2Health News:GSI Group Reports Third Quarter Results 3Health News:GSI Group Reports Third Quarter Results 4Health News:GSI Group Reports Third Quarter Results 5Health News:GSI Group Reports Third Quarter Results 6Health News:GSI Group Reports Third Quarter Results 7Health News:GSI Group Reports Third Quarter Results 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 2Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 3Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 4Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 5Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 6Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 7Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 9Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 10Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 11Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 12Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 3Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 4Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 5Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 6Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 7Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 8Health News:Firing clay in unvented kilns may be a source of exposure to dioxins 2Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 3
... Sterile Bad-Parker blades offer the ... stainless steel technology, plus the exclusive ... and strength. Brad-Parker brand producer offer ... handles and disposable scalpels. Every blade ...
BD Beaver implant blade, 5.1 mm, angled 45, bevel up. matte finish. Designed for widening the incision for lens implantation. Beaver implant blades put precision and control in your hands, sterile....
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
... fit standard trial frames. They are made of optical ... display box. There are two sets available providing a ... that is that a patient can wear the prism ... allow the patient to adapt to the use of ...
Medicine Products: